Flagship Ventures Fund IV General Partner LLC

This profile gathers the share dealings of Flagship Ventures Fund IV General Partner LLC across 2 companies, led by Axcella Health Inc. and Evelo Biosciences, Inc. The record holds 4 filings, for trades running from 16 March 2022 to 11 July 2023.

The open-market record is one-sided, with 4 purchases worth €11.2M and not one sale. The amount is not disclosed for 2 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2023 to date brings 1 purchase and no sales.

The newest entry dates from 13 July 2023: an open-market purchase, in Evelo Biosciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.